Exploring apoptotic pathways in SH-SY5Y neuroblastoma cells: combined effects of napabucasin and doxorubicin
Abstract
Background: Neuroblastoma often begins in infancy and one of the most common types of cancer among children is someone. Napabucasin (NP) (BBI608), a natural naphthoquinone emerging as a novel inhibitor of STAT3, has been found to effectively kill cancer stem-like tumor cells. On the other hand, the effect of Napabucasin on SH-SY5Y cells is currently unclear. The effects and mechanisms of NP and doxorubicin (DX) on human metastatic neuroblastoma cells were investigated.
Materials and methods: In this study, human neuroblastoma cells line (SHSY-5Y) were used. Apoptotic activation of NP and DX via the Bcl-2/Bax signaling pathway was evaluated by qRT-PCR, western blot and Tali cytometry. It was also detected by MTT, a cell viability test.
Results: NP and DX antiproliferative and invasive effected to SH-SY5Y cells. Additionally, NP induced apoptosis by pausing the cell cycle. Moreover, NP treatment inhibited the expression of Bcl-2, which is associated with apoptosis, while it clearly inhibited the expression of Bax and CASP3 genes.
Conclusions: As a results showed that NP and DX suppressed the proliferation of neuroblastoma cells and could do this through apoptotic pathways. NP can be used to suppress metastasis of SHSY-5Y cells as an inhibitor of the apoptosis pathway Bcl-2. It is thought that NP, which provides tumor suppression through an apoptotic mechanism, may be an alternative treatment agent in neurological cancers such as neuroblastoma.
Keywords: napabucasinapoptosisSH-SY5Yneuroblastomadoxorubicin
References
- Bahreyni A, Mohamud Y, Luo H. Recent advancements in immunotherapy of melanoma using nanotechnology-based strategies. Biomed Pharmacother. 2023; 159: 114243.
- Beierle EA, Ma X, Stewart J, et al. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle. 2014; 9(5): 1005–1015.
- Bi S, Chen K, Feng L, et al. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage. Eur J Pharmacol. 2019; 855: 252–261.
- Bitsch R, Kurzay A, Özbay Kurt F, et al. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. J Immunother Cancer. 2022; 10(3).
- Han D, Yu T, Dong N, et al. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019; 38(1): 289.
- Hayashi M, Okabe K, Kato K, et al. Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells. Cancer Lett. 2012; 316(1): 91–96.
- Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013; 23(6): 839–852.
- Lee S, Qiao J, Paul P, et al. Integrin β1 is critical for gastrin-releasing peptide receptor-mediated neuroblastoma cell migration and invasion. Surgery. 2013; 154(2): 369–375.
- Letwin L, Malek L, Suntres Z, et al. Cytotoxic and antibiotic potential of secondary metabolites from the Lichen Umbilicaria muhlenbergii. Curr Pharm Biotechnol. 2020; 21(14): 1516–1527.
- Li H, Qian Y, Wang Xi, et al. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden. Cell Prolif. 2020; 53(1): e12719.
- Li JM, Hsu PC, Kuan FC, et al. The cancer stemness inhibitor napabucasin suppresses small cell lung cancer growth through SOX2 expression. Am J Cancer Res. 2022; 12(10): 4637–4651.
- Li X, Wei Y, Wei X. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma. Cancer Lett. 2020; 491: 146–161.
- Li Ya, Han Q, Zhao H, et al. Napabucasin reduces cancer stem cell characteristics in hepatocellular carcinoma. Front Pharmacol. 2020; 11: 597520.
- Li Y, Rogoff HA, Keates S, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015; 112(6): 1839–1844.
- Li Y, Zheng Y, Liu T, et al. The potential and promise for clinical application of adoptive T cell therapy in cancer. J Transl Med. 2024; 22(1): 413.
- Löcken H, Clamor C, Müller K. Napabucasin and related heterocycle-fused naphthoquinones as STAT3 inhibitors with antiproliferative activity against cancer cells. J Nat Prod. 2018; 81(7): 1636–1644.
- MacDonagh L, Gray SG, Breen E, et al. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett. 2018; 428: 117–126.
- Man J, Yu X, Huang H, et al. Hypoxic induction of vasorin regulates Notch1 turnover to maintain glioma stem-like cells. Cell Stem Cell. 2018; 22(1): 104–118.e6.
- Maomao C, He Li, Dianqin S, et al. Current cancer burden in China: epidemiology, etiology, and prevention. Cancer Biol Med. 2022; 19(8): 1121–1138.
- Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 2007; 369(9579): 2106–2120.
- Muller AG, Sarker SD, Saleem IY, et al. Delivery of natural phenolic compounds for the potential treatment of lung cancer. Daru. 2019; 27(1): 433–449.
- Roy R, Singh SK, Misra S. Advancements in cancer immunotherapies. Vaccines (Basel). 2022; 11(1).
- Shao Z, Wang H, Ren H, et al. The anticancer effect of napabucasin (BBI608), a natural naphthoquinone. Molecules. 2023; 28(15): 5678.
- Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1): 7–33.
- Solárová Z, Liskova A, Samec M, et al. Anticancer potential of Lichens' secondary metabolites. Biomolecules. 2020; 10(1).
- Sun W, Bao J, Lin W, et al. 2-Methoxy-6-acetyl-7-methyljuglone (MAM), a natural naphthoquinone, induces NO-dependent apoptosis and necroptosis by H2O2-dependent JNK activation in cancer cells. Free Radic Biol Med. 2016; 92: 61–77.
- Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11): 736–746.
- Zhang Y, Jin Z, Zhou H, et al. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med. 2016; 5(6): 1251–1258.
- Zuo D, Shogren KL, Zang J, et al. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells. J Exp Clin Cancer Res. 2018; 37(1): 244.
